NVCR - NovoCure Limited

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $33.50 DETAILS

Stock News

3 Overlooked Stocks Set to Soar in 2026

These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.

May 05, 2026 04:45 AM • fool.com

International Markets and NovoCure (NVCR): A Deep Dive for Investors

Review NovoCure's (NVCR) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

May 04, 2026 06:16 AM • zacks.com

NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet

NovoCure Limited has resolved its CMS billing issue, with no material impact on operations or financials. Q1 2026 revenues grew 12% year-over-year to $174.1M; gross margins improved to 78%, and full-year guidance was raised to $690–710M. Optune Pax launch shows promising demand, but sustainability remains uncertain; Optune Lua for lung cancer has disappointed.

May 01, 2026 08:35 AM • seekingalpha.com

NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript

Apr 30, 2026 10:41 AM • seekingalpha.com

NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates

NovoCure (NVCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.31 per share a year ago.

Apr 30, 2026 05:35 AM • zacks.com

Novocure Reports First Quarter 2026 Financial Results

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This was a very strong start to the year for Novocure and we are pleased with the progress made across our commercial and clinical programs,” said Frank.

Apr 30, 2026 03:00 AM • businesswire.com

NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Hold” by Analysts

Shares of NovoCure Limited (NASDAQ: NVCR - Get Free Report) have received an average rating of "Hold" from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have assigned a buy recommendation to the

Apr 24, 2026 10:30 PM • defenseworld.net

Head to Head Contrast: NovoCure (NASDAQ:NVCR) versus Alterity Therapeutics (NASDAQ:ATHE)

NovoCure (NASDAQ: NVCR - Get Free Report) and Alterity Therapeutics (NASDAQ: ATHE - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings. Risk and Volatility NovoCure has a beta of

Apr 15, 2026 09:11 PM • defenseworld.net

JPMorgan Chase & Co. Buys 144,024 Shares of NovoCure Limited $NVCR

JPMorgan Chase and Co. lifted its stake in NovoCure Limited (NASDAQ: NVCR) by 104.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 282,184 shares of the medical equipment provider's stock after buying an additional 144,024 shares during the period. JPMorgan

Apr 04, 2026 12:56 AM • defenseworld.net

Novocure to Report First Quarter 2026 Financial Results

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 30, to discuss the company's financial results for the three-month period that ended March 31, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To acces.

Apr 01, 2026 03:00 AM • businesswire.com

NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer

The stock is gaining traction as the company reported a disease control rate of 74.4%, significantly higher than the historical control of 48%.

Mar 26, 2026 07:19 AM • benzinga.com

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq®), gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). PANOVA-4 met its pre-specified primary endpoint, achieving a statistically significant improvement in disease control rate (DCR) compared to the DCR reported.

Mar 26, 2026 03:00 AM • businesswire.com

Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment

NVCR gains Japan NHI reimbursement for Optune Lua in advanced NSCLC, expanding patient access and supporting adoption of its TTFields cancer therapy platform.

Mar 09, 2026 08:56 AM • zacks.com

NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know

Explore NovoCure's (NVCR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Mar 02, 2026 05:16 AM • zacks.com

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country's National Health Insurance coverage. Optune Lua is approved in Japan for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on or after platinum-based chemotherapy. “Lung cancer remains one of the leading causes of cancer deaths in Japan. Healt.

Mar 02, 2026 02:00 AM • businesswire.com

Novocure to Participate in 2026 Leerink Global Healthcare Conference

BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Participate in 2026 Leerink Global Healthcare Conference.

Feb 27, 2026 11:30 AM • businesswire.com

NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates

NovoCure (NVCR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.61 per share a year ago.

Feb 26, 2026 08:21 AM • zacks.com

NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript

Feb 26, 2026 06:17 AM • seekingalpha.com

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update.

Feb 26, 2026 02:00 AM • businesswire.com

Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the province of British Columbia, Canada, will now cover Tumor Treating Fields (TTFields) therapy for the treatment of adult patients with newly diagnosed glioblastoma. British Columbia is the first province to provide coverage following Canada's Drug Agency's assessment and reimbursement recommendation for TTFields therapy in glioblastoma. “Glioblastoma is one of the most aggressive cancers, and treatment options.

Feb 24, 2026 02:00 AM • businesswire.com